BlackRock
SPRY icon

BlackRock’s ARS Pharmaceuticals SPRY Stock Holding History

BlackRock’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.2M Sell
5,012,254
-73,063
-1% -$700K ﹤0.01% 2650
2025
Q4 		$59.2M Buy
5,085,317
+253,990
+5% +$2.47M ﹤0.01% 2414
2025
Q3 		$48.6M Buy
4,831,327
+407,863
+9% +$5.85M ﹤0.01% 2520
2025
Q2 		$77.2M Buy
4,423,464
+124,476
+3% +$1.8M ﹤0.01% 2216
2025
Q1 		$54.1M Sell
4,298,988
-275,503
-6% -$3.31M ﹤0.01% 2334
2024
Q4 		$48.3M Buy
4,574,491
+328,517
+8% +$4.6M ﹤0.01% 2473
2024
Q3 		$61.6M Buy
4,245,974
+161,635
+4% +$1.92M ﹤0.01% 2350
2024
Q2 		$34.8M Buy
4,084,339
+1,426,100
+54% +$12.7M ﹤0.01% 2637
2024
Q1 		$27.2M Buy
2,658,239
+20,690
+0.8% +$154K ﹤0.01% 2816
2023
Q4 		$14.5M Buy
2,637,549
+70,765
+3% +$310K ﹤0.01% 3195
2023
Q3 		$9.7M Buy
2,566,784
+305,864
+14% +$2.01M ﹤0.01% 3351
2023
Q2 		$15.1M Buy
2,260,920
+1,142,355
+102% +$7.62M ﹤0.01% 3200
2023
Q1 		$7.28M Buy
1,118,565
+215,020
+24% +$1.65M ﹤0.01% 3473
2022
Q4 		$7.71M Buy
903,545
+175,841
+24% +$1.14M ﹤0.01% 3512
2022
Q3 		$3.84M Buy
727,704
+19,859
+3% +$97.9K ﹤0.01% 3873
2022
Q2 		$3M Sell
707,845
-899,655
-56% -$3.14M ﹤0.01% 4059
2022
Q1 		$5.64M Buy
1,607,500
+28,213
+2% +$123K ﹤0.01% 3895
2021
Q4 		$10.5M Buy
1,579,287
+351,626
+29% +$2.86M ﹤0.01% 3643
2021
Q3 		$12.3M Buy
1,227,661
+348,296
+40% +$8.59M ﹤0.01% 3581
2021
Q2 		$27.2M Sell
879,365
-339,903
-28% -$10.9M ﹤0.01% 3115
2021
Q1 		$53.2M Buy
1,219,268
+829,107
+213% +$39.2M ﹤0.01% 2571
2020
Q4 		$18.1M Buy
+390,161
New +$13M ﹤0.01% 3061

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $921M AUM 60.37% 1-Year Est. Return

BlackRock's SPRY Position: Q1 2026 in Review

BlackRock reduced its ARS Pharmaceuticals (SPRY) stake by 1.4% in Q1 2026, selling an estimated $700K and leaving 5,012,254 shares worth $40.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2650.

BlackRock first reported a position in SPRY in Q4 2020 and has held it in 22 quarters since. The position peaked at $77.2M in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • BlackRock held 5,012,254 shares of ARS Pharmaceuticals worth $40.2M as of Q1 2026.
  • BlackRock sold 73,063 ARS Pharmaceuticals shares in Q1 2026, an estimated $700K.
  • ARS Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2650 holding.
  • BlackRock first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • BlackRock's ARS Pharmaceuticals position peaked at $77.2M in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.